Refractory angina pectoris: Mechanism and therapeutic options

Journal of the American College of Cardiology

Volumn 39, Issue 6, 2002, Pages 923-934

  Kim, Michael ^a   Kini, Annapoorna ^a   Sharma, Samin ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BASIC FIBROBLAST GROWTH FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDETIC ACID; FATTY ACID OXIDATION INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; NIFEDIPINE; NITRATE; PARNAPARIN; PERINDOPRIL; PLACEBO; RAMIPRIL; RANOLAZINE; RECOMBINANT FIBROBLAST GROWTH FACTOR; TICLOPIDINE; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN; VERAPAMIL;

ANGINA PECTORIS; ANTICOAGULATION; CHELATION THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COUNTERPULSATION; GENE THERAPY; HEART TRANSPLANTATION; HUMAN; LASER SURGERY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; SPINAL CORD STIMULATION; THERAPY RESISTANCE; TRANSCUTANEOUS NERVE STIMULATION;

ANGINA PECTORIS; EUROPE; HUMANS; TREATMENT OUTCOME; UNITED STATES;

EID: 0037139277     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)01716-3     Document Type: Review

References (55)

1. Direct myocardial revascularization and angiogenesis: How many patients might be eligible?
2. Effects of an angiotensin-converting-enzyme inhibitor, ramapril, on cardiovascular events in high-risk patients
3. The evolving role of statins in the management of atherosclerosis
4. Effect of stain therapy on C-reactive protein levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study
5. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
6. Current oral antiplatelet agents to prevent atherothrombosis
7. Results of the CURE trial for acute coronary syndrome
8. Low-molecular-weight heparins
9. Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris: A double-blind randomized, placebo-controlled trial
10. Angiogenic effects of low molecular weight heparin in patients with stable coronary artery disease: A pilot study
11. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI-IIIB trial
12. Chronic-intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: A pilot study
13. Long-term intermittent urokinase therapy in patients with end-stage coronary artery disease and refractory angina pectoris: A randomized dose-response trial
14. Late breaking trial results: The CARISA trial
15. The effects of transcutaneous electrical stimulation in patients with severe angina pectoris
16. Effect of spinal cord stimulation on heart rate variability and myocardial ischemia in patients with chronic intractable angina pectoris: A prospective ambulatory electrocardiographic study
17. Spinal cord stimulation for chronic intractable angina pectoris: A unified theory on its mechanism
18. Epidural spinal electrical stimulation in severe angina pectoris
19. Spinal cord stimulation in chronic intractable angina pectoris: A randomized, controlled efficacy study
20. Electrical stimulation versus coronary artery bypass surgery in severe angina pectoris: The ESBY study
21. Spinal cord stimulation for the treatment of refractory angina pectoris: A two-year follow up
22. Enhanced external counterpulsation in the management of patients with cardiovascular disease
23. The Multicenter Study of Enhanced External CounterPulsation (MUST-EECP): Effect of EECP on exercise-induced myocardial ischemia and anginal episodes
24. Enhanced external counterpulsation improves exercise tolerance, reduces exercise-induced myocardial ischemia and improves left ventricular diastolic filling in patients with coronary artery disease
25. The International EECP Patient Registry (IEPR): Design, methods, baseline characteristics, and acute results
26. The nature of the vascular communications between the coronary arteries and the chambers of the heart
27. Clinical and experimental studies in the treatment of coronary artery insufficiency by internal mammary artery implant
28. Alternative method of myocardial revascularization by laser: Experimental and clinical study
29. Transmyocardial laser revascularization: Results of a multicenter trial with transmyocardial laser revascularization used as sole therapy for end-stage coronary artery disease
30. Transmyocardial laser revascularization in patients with refractory angina: A randomized controlled trial
31. Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease
32. Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina
33. Transmyocardial laser revascularization compared with continued medical therapy for treatment of refractory angina pectoris: A prospective randomized trial
34. Transmyocardial laser revascularization
35. Catheter-based percutaneous myocardial revascularization in patients with end-stage coronary artery disease
36. Percutaneous transmyocardial laser revascularisation for severe angina: The Potential Class Improvement From Intramyocardial Channels (PACIFIC) randomized trial
37. Therapeutic angiogenesis
38. Clinical evidence of angiogenesis after arterial gene transfer of ph VEGF 165 in patient with ischaemic limb
39. Constitutive expression of ph VEGF 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
40. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of ph VEGF 165 as sole therapy for myocardial ischemia
41. Angiogenesis gene therapy: Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease
42. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial
43. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and rest myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease
44. Left ventricular electromechanical mapping to assess efficacy, of ph VEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia
45. Late breaking trial results: The AGENT trial
46. Coronary venous retroperfusion for myocardial revascularization
47. Percutaneous in situ coronary venous arterialization: Report of the first human catheter-based coronary artery bypass
48. New approaches and conduits: In situ venous arterialization and coronary artery bypass
49. Chelation therapy for coronary heart disease: An overview of all clinical investigations
50. Cheladon therapy for ischemic heart disease: A randomized controlled trial
51. The Registry of the International Society for heart and lung transplantation: Thirteenth official report - 1999